<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>use of a high resolution MRM approach to develop assays forbiologically important tear proteins.Methods: Human tear samples were collected from 1000 consentingpatients with no eye complaints (411 male, 589 female, average age55.5 years, SD 14.5 years) using the Schirmer tear test strips andpooled into a single global control sample. Quantification of proteinsis carried out by selecting “signature” peptides derived by trypsindigestion of the target protein. A 2-hour nanoLC-MS/MS run wasused to separate the tryptic peptides and perform quantitation ofhuman tear proteins in HR-MRM mode. Samples were analyzed intriplicate. Twenty-one high abundant proteins were further accessedfor signal reproducibility.Results: Fifty-three peptide assays that represent 51 high andintermediate abundant tear proteins were developed. All assaysshowed consistent retention time with a coefficient of variation (CV)of less than 2%. As for peak area, 17 out of the 21 assays showed areproducible peak area with CV less than 20%. Some wellcharacterized tear proteins, lacritin, mammaglobin-B, S100A4,S100A8, and prolactin inducible protein (PIP) showed the highestreproducibility of peak area, with CV less than 2%.Conclusions: These multiplexed MRM-based assays show greatpromise to be further developed for biomarker validation in humantear samples.Commercial Relationships: Lei Zhou, Singapore Eye ResearchInstitute (P); Louis Tong, None; Roger W. Beuerman, Allergan (F),SERI (P), Santen (R)Support: CG from NMRC, Singapore, Core facility funding fromSingHealth Foundation283 EndotheliumMonday, May 06, 2013 2:45 PM-4:30 PMTCC 304 Paper SessionProgram #/Board # Range: 2196-2202Organizing Section: <strong>Cornea</strong>Program Number: 2196Presentation Time: 2:45 PM - 3:00 PMDecline in DJ-1 Leads to Decreased Nuclear Translocation ofNrf2 and Results in p53-mediated Apoptosis of Human <strong>Cornea</strong>lEndothelial CellsCailing Liu, Yuming Chen, Ula V. Jurkunas. Schepens/MassachusettsEye and Ear, Department of Ophthalmology, Harvard MedicalSchool, Boston, MA.Purpose: Dowregulation of DJ-1 and decreased nuclear localizationof nuclear factor erythroid-derived 2-like 2 (Nrf2) has been detectedin Fuchs endothelial corneal dystrophy endothelium. DJ-1 has beenreported to stabilize Nrf2, which binds to antioxidant responseelement in the nucleus to protect cells from apoptosis. In this study,we investigated the effect of DJ-1 downregulation on Nrf2 nucleartranslocation, Nrf2-associated protein regulation, and cornealendothelial cell susceptibility to oxidative stress.Methods: An immortalized normal human corneal endothelial cellline (HCECi) was transfectedwith 50 nM of siRNA specific to the human DJ-1 gene usingLipofectamine. Scrambled siRNA was used as control. Nrf2 and p53levels in nuclear and cytosolic extracts were evaluated by westernblotting. Nrf2-associated proteins such as Cul3 and Keap1 weredetected by immunoprecipitation (IP) with anti-Nrf2 antibody,followed by western blotting with target antibodies. Oxidative stresswas induced by exposing HCECi cells to a UVA broadband lampwith the fluence of 10 J/cm 2 . Cell pellets were harvested for westernblotting with anti-caspase 3 and p53 antibodies, while supernatantswere collected for a cell viability assay.Results: Despite similar levels of cytoplasmic Nrf2, nuclear Nrf2protein levels decreased by 2.2-fold (p=0.04) in DJ-1 siRNA-treatedHCECi cells as compared to scrambled siRNA-treated cells. IPstudies detected Nrf2 association with Cul3 and Keap1 with anincrease in Cul3-Nrf2 complex in DJ-1 siRNA-treated cells relativeto controls. UVA irradiation led to an 8.5% increase in cell death inDJ-1 siRNA-treated cells as compared to controls. Moreover,downregulation of DJ-1 led to a 16.4% increase in active caspase 3levels. This effect was augmented by UVA treatment, which led to a28.6% increase in caspase 3 as compared to controls. Downregulationof DJ-1 resulted in an increase in cytoplasmic p53 levels, while UVAirradiation resulted in a 17.7% increase in total p53 levels in DJ-1siRNA treated cells as compared to controls.Conclusions: Downregulation of DJ-1 impairs nuclear translocationof Nrf2 potentially by targeting Nrf2 for degradation through Cul3and Keap1 pathways. Decline in DJ-1 levels leads to heightened cellsusceptibility to UVA-induced apoptosis and activates p53-dependentpathway in corneal endothelium.Commercial Relationships: Cailing Liu, None; Yuming Chen,None; Ula V. Jurkunas, 61/482,769 (P), Altheos (C)Support: NIH/NEI Grant R01 EY20581 (UVJ), a Research toPrevent Blindness Award (UVJ)Program Number: 2197Presentation Time: 3:00 PM - 3:15 PMMicroRNA Analysis in Fuchs Endothelial <strong>Cornea</strong>l DystrophyMario Matthaei 1, 2 , Jianfei Hu 1 , Laura Kallay 1 , Claus Cursiefen 2 ,Jiang Qian 1 , Albert S. Jun 1 . 1 Anterior Segment / <strong>Cornea</strong>, Wilmer EyeInst, Johns Hopkins Univ, Baltimore, MD; 2 Department ofOphthalmology, University of Cologne, Cologne, Germany.Purpose: MicroRNAs (miRNAs) are a class of endogenousnoncoding RNA which posttranscriptionally modulate geneexpression during development and disease. Our study investigatedthe differential miRNA expression pattern in human FuchsEndothelial <strong>Cornea</strong>l Dystrophy (FECD) compared to normalendothelium.Methods: Total RNA was extracted from corneal endothelial cells ofFECD eyes (n=6) and age-matched normal autopsy globes (n=6). Theexpression of 754 well characterized miRNA sequences was analyzedin preamplified cDNA samples using OpenArray plate technology onthe QuantStudio 12K Flex system for high-throughput real-timequantification and individual targets were validated by Taqman qPCRassays.Results: We detected differential expression of at least 37microRNAs using global normalization and applying a fold-changeof 2 and p=0.05 as cut-off values. Of these 37 miRNAs, 32 showeddownregulation whereas 5 miRNAs were upregulated. MiRNA targetgenes were predicted and further analyzed by gene ontologyassessment.Conclusions: We present the first endothelial cell microRNA profilein FECD and normal endothelial samples and identify dysregulatedmiRNA expression in FECD.Commercial Relationships: Mario Matthaei, None; Jianfei Hu,None; Laura Kallay, None; Claus Cursiefen, Gene Signal (C),Alcon (R), Allergan (R), Bayer (R); Jiang Qian, None; Albert S.Jun, Johns Hopkins University (P)Support: Deutsche Forschungsgemeinschaft (DFG MA 5110/2-1 toM.M.), Richard Lindstrom/Eye Bank Association of AmericaResearch Grant (to M.M.), National Institutes of Health (EY019874to A.S.J.), Research to Prevent Blindness (to Wilmer Eye Institute)Program Number: 2198©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>Presentation Time: 3:15 PM - 3:30 PMIdentification of New markers of Human <strong>Cornea</strong>l EndothelialCellsJodhbir S. Mehta 1 , Adrian Cheong 2 , Gary S. Peh 1 , William Sun 2 .1 <strong>Cornea</strong> Refractive Tissue Engineering, SNEC / SERI, Singapore,Singapore; 2 Experimental Therapeutic Unit, A Star, Singapore,Singapore.Purpose: There are no specific markers of human corneal endothelialcells (HCEC). Currently, the identification of HCEC in culture reliesmainly on expression of pump or tight junction markers.The aim ofthis study is to describe new HCEC markers.Methods: Isolated human corneal DM-HCEC and remaining stromafrom corneal donors were homogenized individually for RNAsequencing. RNA-seq libraries were prepared using AB protocol fornon-barcoded libraries and SOLiD fragment library for barcodedlibrary. The results were processed using ABI Bioscope. Geneexpression was measured by counting the number of reads mappinguniquely to both strands of each gene footprint. Results were verifiedby quantitative PCR, BD lyoplate screening, immunofluorescenceand flow cytometry using cultivated primary HCEC isolated andgrown to the third passage.Results: RNA-seq showed 5 genes that were over expressed in theHCEC-DM compared to stromal fibroblasts, GPC4, CNTN6,SLC9A7, PVRL3, and SLC4A4. The resulting over-expression ofthese genes was confirmed on comparing qPCR data from culturedHCEC and stromal fibroblasts. BD lyoplate identified CD104 andCD200 as potential markers. On immuno-histochemistry anti-GPC4,anti-CD200 and anti-SLC4A cell-surface antibodies clearly stainedthe the endothelial layer specifically. In a population of pre-CMFDAlabelled stromal fibroblasts and HCEC, mixed in a 1:1ratiofluorescent-activated cell sorting (FACS) showed a 96% recovery ofHCEC when sorted with anti-GPC4 and a 79.8% with anti-CD200.Conclusions: By RNA sequencing verified on qPCR andimmunohistochemistry we have identified two novel cell surfaceantigens on human corneal endothelial cells. These markers may beused to aid cell purification during harvesting or in the identificationof cultured HCEC to ensure quality control of cultured cells.Commercial Relationships: Jodhbir S. Mehta, None; AdrianCheong, None; Gary S. Peh, Singapore Eye Research Institute (P);William Sun, NoneSupport: NMRC TCRP 2011Program Number: 2199Presentation Time: 3:30 PM - 3:45 PMTight Junction Transmembrane Protein Claudin SubtypeExpression and Distribution in Human <strong>Cornea</strong>l EndotheliumEmi Inagaki, Shin Hatou, Satoru Yoshida, Hideyuki Miyashita, KazuoTsubota, Shigeto Shimmura. Ophthalmology, Keio University,Tokyo, Japan.Purpose: The primary function of corneal endothelium is to maintaincorneal transparency by regulating corneal hydration and nutritionmodulated by barrier and metabolic pump function. However, themolecular mechanism of its barrier function is still relativelyunknown. Claudins, recently identified main components of tightjunctions,are a family of four-transmembrane-spanning proteins. Todate, 24 subtype of claudins have been identified in human.Combination of claudin subtypes may contribute not only to thetightness of tight junction strands but also ion-selective channels. Inthis study, we investigated the expression and pattern of claudins inin vivo human cornea.Methods: The experiments in this paper used remained corneal tissuesupplied from USA eye bank after the central buttons were used forcorneal transplantation. We stripped corneal endothelium withDescemet membrane and corneal epithelium from corneal stroma.Reverse transcription-polymerase (RT-PCR) was performed toevaluate that subtypes of claudins expressed in corneal endothelium,stroma and endothelium. Then, immunohistochemistry wasperformed for claudins positively expressed in RT-PCR, to confirmwhether they would express lateral side of corneal endothelium.Results: Transcripts for claudin-1, -2, -3, -4,-7, -10b, -11,-12,-14, -15, -22, -23, and -24 were identified in human corneal endothelium inRT-PCR. Claudin-1, -2, -3, -4, -7 , -11, -12, -14, -15, -22, -23, and -24 expression in corneal endothelium was common to cornealepithelium, and claudin-1, -2,-3,-4, -7, -11,-12,-14, -15, -22,-23,and -24 was common to corneal stroma. Among the claudin subtypesexpressed in corneal endothelium, immunohistochemistry revealedthe expression of claudin-1,-2, -4, -7, -10 antibodies showed bandsthat correspond to the junctional complex. Claudin-11 was alsoexpressed in corneal endothelium, however, the expression was notcontinuous but in a dotlike pattern along cell junctions.Conclusions: Claudin-1, -2, -4,-7, -10b and -11 are expressed incorneal endothelium. This combination of claudin subtype maycontribute to the uniqueness of barrier integrity and ion sensitivity incorneal endothelium.Commercial Relationships: Emi Inagaki, None; Shin Hatou,None; Satoru Yoshida, None; Hideyuki Miyashita, None; KazuoTsubota, AcuFocus, Inc (C), Allergan (F), Bausch Lomb Surgical(C), Functional visual acuity meter (P), JiNS (P), Kissei (F), Kowa(F), Santen, Inc. (F), Otsuka (F), Pfizer (C), Thea (C), Echo Denki(P), Nidek (F), Ophtecs (F), Wakasa Seikatsu (F), CEPT Company(P); Shigeto Shimmura, NoneProgram Number: 2200Presentation Time: 3:45 PM - 4:00 PM<strong>Cornea</strong>l endothelial cells provide evidence of accelerated cellularsenescence associated with HIV infection: a case-control studySophia Pathai 1, 2 , Stephen D. Lawn 3, 2 , Paul G. Shiels 5 , Helen A.Weiss 4 , Colin Cook 6 , Robin Wood 2 , Clare E. Gilbert 1 . 1 InternationalCentre for Eye Health, London School of Hygiene & TropicalMedicine, London, United Kingdom; 2 Desmond Tutu HIV Centre,University of Cape Town, Cape Town, South Africa; 3 Dept ofClinical Research, London School of Hygiene & Tropical Medicine,London, United Kingdom; 4 MRC Tropical Epidemiology Group,London School of Hygiene & Tropical Medicine, London, UnitedKingdom; 5 Dept of Epigenetics, Institute of Cancer Sciences,University of Glasgow, Glasgow, United Kingdom; 6 Dept ofOphthalmology, University of Cape Town, Cape Town, South Africa.Purpose: Cellular senescence may be a key factor in HIV-relatedpremature biological aging. We assessed features of the cornealendothelium that are known to be associated with biological aging,and cellular senescence markers in HIV-infected adults.Methods: Case-control study of 242 HIV-infected adults and 249matched controls. Using specular microscopy, the cornealendothelium was assessed for features of aging (low endothelial celldensity [ECD], high variation in cell size, and low hexagonalityindex). Data were analysed by multivariable regression. CDKN2A (acell senescence mediator) and 8-hydroxy-2′-deoxyguanosine (anoxidative DNA damage marker) were measured in peripheral bloodleukocytes.Results: The median age of both groups was 40 years. Among HIVinfectedadults, 88% were receiving antiretroviral therapy (ART);their median CD4 count was 468 cells/μL. HIV infection wasassociated with increased odds of variation in cell size (OR=1.67;95%CI: 1.00-2.78, p=0.04). Among HIV-infected participants, lowECD was independently associated with current CD4 count
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35:
ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37:
ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39:
ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41:
ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43:
ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45:
ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47:
ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49:
ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51:
ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53:
ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55:
ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57:
ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59:
ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61:
ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63:
ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65:
ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67:
ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69:
ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71:
ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73:
ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75:
ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77:
ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79:
ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81:
ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83:
ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85:
ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87:
ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89:
ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91:
ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95:
ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97:
ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99:
ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101:
ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103:
ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105:
ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107:
ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109:
ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111: ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113: ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115: ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117: ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119: ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121: ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123: ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125: ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127: ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129: ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131: ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133: ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135: ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137: ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139: ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141: ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143: ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145: ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147: ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149: ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151: ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153: ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155: ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157: ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159: ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163: ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165: ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167: ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169: ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171: ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173: ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175: ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177: ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179: ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181: ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183: ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185: ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187: ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189: ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191: ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193: ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195: ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197: ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199: ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201: ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203: ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205: ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207: ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209: ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211:
ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213:
ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215:
ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217:
ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219:
ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221:
ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223:
ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225:
ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227:
ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229:
ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231:
ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233:
ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235:
ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237:
ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239:
ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241:
ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243:
ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245:
ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247:
ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249:
ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251:
ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253:
ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255:
ARVO 2013 Annual Meeting Abstracts
- Page 256 and 257:
ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259:
ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261:
ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263:
ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265:
ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267:
ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269:
ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271:
ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273:
ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275:
ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277:
ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279:
ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281:
ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283:
ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285:
ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287:
ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289:
ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291:
ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293:
ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295:
ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297:
ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299:
ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301:
ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303:
ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305:
ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts